Business Context and Reporting Period
Company: Cognition Therapeutics, Inc. (CGTX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2026
Reporting Period: Single event date (June 4, 2026)
Business Context: The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Purchase, NY. The filing serves as a Regulation FD disclosure to furnish an investor presentation to the public.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of an investor presentation (Exhibit 99.1) rather than a financial statement report containing audited or unaudited financial data.
Material Changes
No material changes to financial position or operations are detailed in the text of this filing. The document solely announces the availability of an investor presentation for use in discussions with investors and analysts.
Guidance, Outlook, and Risks
Management Commentary: The company furnished an investor presentation (Exhibit 99.1) which may contain forward-looking statements, though the specific content of the presentation is not included in the text of this filing.
Regulatory Status: The information furnished is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. It shall not be incorporated by reference into other filings unless specifically referenced.
Risks: No specific risks or contingencies are enumerated in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation) for specific operational updates, clinical trial data, or financial guidance not present in the 8-K text.
- Verify the company's status as an "Emerging Growth Company" and its implications for financial reporting standards.
- Confirm the trading symbol (CGTX) and exchange (Nasdaq) for current market data.
- Note that the filing explicitly disclaims the "filed" status of the attached presentation for liability purposes under Section 18 of the Exchange Act.